Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Spotlight Correspondence
  • Published:

Does post-transplant treatment with imatinib mesylate inhibit graft-versus-leukemia?

Leukemia volume 19, pages 456–457 (2005)Cite this article

TO THE EDITOR

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Cwynarski K, Laylor R, Macchiarulo E, Goldman J, Lombardi G, Melo JV et al. Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro. Leukemia 2004; 18: 1332–1339.

    Article  CAS  Google Scholar 

  2. Dietz AB, Souan L, Knutson GJ, Bulur PA, Litzow MR, Vuk-Pavlovic S . Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. Blood 2004; 104: 1094–1099.

    Article  CAS  Google Scholar 

  3. Thiede C, Florek M, Bornhauser M, Ritter M, Mohr B, Brendel C et al. Rapid quantification of mixed chimerism using multiplex amplification of short tandem repeat markers and fluorescence detection. Bone Marrow Transplant 1999; 23: 1055–1060.

    Article  CAS  Google Scholar 

  4. Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N et al. Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – a Europe Against Cancer program. Leukemia 2003; 17: 2318–2357.

    Article  CAS  Google Scholar 

  5. Kim YJ, Kim DW, Lee S, Kim YL, Hwang JY, Park YH et al. Cytogenetic clonal evolution alone in CML relapse post-transplantation does not adversely affect response to imatinib mesylate treatment. Bone Marrow Transplant 2004; 33: 237–242.

    Article  CAS  Google Scholar 

  6. Shimoni A, Kroger N, Zander AR, Rowe JM, Hardan I, Avigdor A et al. Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias. Leukemia 2003; 17: 290–297.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Stem Cell Transplant Program – Section of Hematology/Oncology, University of Illinois at Chicago, Chicago, Illinois, USA

    S Chunduri, L C Dobogai & D Rondelli

  2. Department of Pathology, University of Illinois at Chicago, Chicago, Illinois, USA

    A Bruno & S Kadkol

Authors
  1. S Chunduri
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L C Dobogai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Bruno
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S Kadkol
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D Rondelli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D Rondelli.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chunduri, S., Dobogai, L., Bruno, A. et al. Does post-transplant treatment with imatinib mesylate inhibit graft-versus-leukemia?. Leukemia 19, 456–457 (2005). https://doi.org/10.1038/sj.leu.2403656

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2403656

This article is cited by

Search

Advanced search

Quick links